NICE gives a preliminary no to Avastin for bowel cancer
This article was originally published in Scrip
NICE, the health technology appraisal body for England and Wales, has given a preliminary no to funding Roche's Avastin (bevacizumab) for NHS patients with advanced bowel cancer. However, the firm says it hopes to change the institute's mind.
You may also be interested in...
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.
EFPIA, the European Federation of Pharmaceutical Industries and Associations, has put forward what it thinks the European regulatory network strategy to 2025 should prioritize.